Sunovion reports positive top-line results from Phase III trial of latuda for bipolar depression

US-based biopharmaceutical company Sunovion Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of latuda (lurasidone HCl) for the treatment of depression associated with bipolar I disorder (bipolar depression).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news